Can-Fite Biopharma
$1.45 +0.0100 +2.11% 112.3K
Small Molecules for Big Clinical Needs
Company Overview
Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of NASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.
Value Proposition
Can-Fite BioPharma is focused on developing small molecule drugs targeting the A3 adenosine receptor (A3AR), a unique approach in treating pathological conditions including cancer and inflammatory diseases. The Company’s robust pipeline includes advanced-stage clinical candidates demonstrating promising efficacy and safety profiles for psoriasis, liver diseases, and pancreatic cancer.
Strategically positioned with multiple out-licensing deals and potential milestone payments totaling over $455 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. The Company has secured Fast Track and Orphan Drug designations (ODD) from the FDA and EMA for its liver disease candidate and ODD from the FDA for its pancreatic cancer candidate, enhancing regulatory pathways.
With advanced-stage assets targeting unmet medical needs in markets with a combined value more than $70 billion, Can-Fite is well positioned for the potential commercialization of its innovative therapies and has buy ratings from HC Wainwright and Alliance Global Partners with a median price target of $15 per share.
Partnerships and Out-Licensing Deals
Investor Presentation
Investment Highlights
Oral drugs with proven safety and efficacy in pivotal Phase III studies
- Piclidenoson and Namodenoson are Phase III assets in psoriasis and liver cancer
- Namodenoson showed strong efficacy in a Phase II SLD study and is headed into an exploratory Phase IIa study in pancreatic cancer
- Significant positive results from osteoarthritis Phase IIa clinical study of Piclidenoson in dogs.
Monetizing advanced portfolio through corporate partnerships
- Piclidenoson and Namodenoson have been out-licensed in select territories with ~$20 million received to date and potentially up an additional $130 million plus royalties
- Partnered with Vetbiolix to commercialize with projected income of $325M to Can-Fite over 10 years from upfront, milestone, and royalty payments
Novel therapeutic approach
- Unique technology for the treatment of cancer, liver and inflammatory diseases
- Diverse portfolio addresses large markets ($70B+) with significant unmet needs
Proven safety and efficacy
- Drugs have shown high efficacy and good safety in clinical trials involving over 1,600 patients
Strong Intellectual property portfolio
- 15 patent families issued and pending
Financially well positioned
- Sufficient resources to conduct all clinical development programs and cover G&A for more than 12 months
Buy ratings with $15 per share median price target from HC Wainwright and Alliance Global Partners
Development Pipeline
Sign Up For CANF Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2024, for four month of investor awareness services. a one-time cash fees of $50,000, $22,500, $45,000 and $40,000 for national TV ad campaigns aired weekdays from June 3 to June 14, 2024, June 19 to June 25, 2024, October 2 to October 15, 2024, and December 4 to December 17, 2024, respectively.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.